For decades, the “dad bod” was a culturally accepted staple of middle age—a soft silhouette that signaled a transition from the gym-focused intensity of youth to the priorities of fatherhood and professional life. However, a significant shift is occurring in how men over 40 approach their health and appearance. The emergence of GLP-1 receptor agonists—a class of medications including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)—has fundamentally altered the landscape of weight management for men in the public eye.
The pressure to conform to modern aesthetic standards is increasingly impacting middle-aged men. Research suggests that this demographic may struggle with body image more than previously understood; a 2020 study published in BMC Public Health indicated that middle-aged men were more likely to experience a distorted body image than their female counterparts. While the results of these medications are often visually striking, the transition is rarely without complication. From managing “food noise” to navigating severe gastrointestinal side effects, the experiences of high-profile fathers provide a window into the clinical and psychological realities of these drugs.
The decision to go public with GLP-1 leverage is often a calculated move to combat the specific stigma men feel regarding medical weight loss. According to a survey by the Kinsey Institute at Indiana University, men are more likely than women to feel shamed or judged for using these medications. Yet, when they do use them, men report a confidence boost three times more likely than women. By sharing their journeys, several celebrity dads over 40 who have confirmed Ozempic or GLP-1 use are attempting to normalize the treatment of obesity as a chronic medical condition rather than a failure of will.
The Clinical Trade-Off: Successes and Side Effects
For many, the primary appeal of GLP-1s is the silencing of “food noise”—the intrusive, constant thoughts about eating that often plague those struggling with obesity. Josh Gad, the Frozen actor and father of two, described this exact phenomenon during a 2025 appearance on the Armchair Expert podcast, noting that the medication aided his 40-pound weight loss by quieting his mind. His motivation was rooted in longevity: “I want to be there for my kids.”
However, the medical reality of rapid weight loss can be fraught. Gad reported developing diverticulitis—an inflammation of pouches in the colon wall—as a result of his treatment, which necessitated a switch to a different GLP-1 formulation. Similarly, singer Robbie Williams, a father of four, confirmed a 25-pound weight loss using a GLP-1 medication but later reported significant vision blurring. From a clinical perspective, the American Academy of Ophthalmology notes that rapid drops in blood sugar can cause temporary vision changes, though more severe risks like ischemic optic neuropathy remain a subject of ongoing study.
Other users have experienced more common, albeit disruptive, gastrointestinal distress. Elon Musk, a father of 14, has been a vocal proponent of GLP-1s, though he noted that high doses of Ozempic led to excessive burping and flatulence, eventually leading him to switch to Mounjaro. Musk credited a combination of the medication and intermittent fasting for his initial 30-pound weight loss.
Navigating Shortages and Metabolic Shifts
The efficacy of these drugs is often hampered by a volatile supply chain. For some, the “Ozempic effect” is temporary, not given that of biological resistance, but because of pharmacy shortages. NBA legend Charles Barkley, a father of one, shared that he gained 105 pounds following hip surgery and struggled to lose it naturally due to an age-related metabolic slowdown. While Mounjaro helped him shed 65 pounds and reduce joint pain, he was unable to maintain the regimen due to national drug shortages.
Jon Gosselin experienced a similar roadblock. After losing 32 pounds in two months, the father of eight reported that the return of hunger pangs and subsequent weight regain occurred when the medication became unavailable. This highlights a critical medical concern: the “rebound effect” that often occurs when GLP-1 therapy is discontinued abruptly without a comprehensive maintenance plan.
| Celebrity | Medication Used | Reported Outcome/Side Effect |
|---|---|---|
| Elon Musk | Mounjaro / Ozempic | 30 lb loss; GI distress (burping) |
| Charles Barkley | Mounjaro | 65 lb loss; interrupted by shortages |
| Josh Gad | GLP-1 (Unspecified) | 40 lb loss; developed diverticulitis |
| Jim Gaffigan | Mounjaro | 50 lb loss; used for appetite control |
| Robbie Williams | GLP-1 (Unspecified) | 25 lb loss; reported blurry vision |
Health-Driven Use and Lifestyle Integration
While some use these drugs for aesthetic reasons, others utilize them to manage comorbid health conditions. Fat Joe, a father of three, revealed he has lost 250 pounds over a decade through a combination of low-carb dieting and Ozempic, the latter of which he used specifically for diabetes management. He described the medication as a powerful appetite suppressant that helped him finish the final leg of his weight loss journey.
Similarly, Andy Cohen, a father of two, disclosed that he used a “micro-dosing” approach to GLP-1s to curb cravings. For Cohen, the decision was driven by clinical markers, including high blood pressure and plaque build-up in his arteries. He described the medication as a catalyst that encouraged him to seize his overall health and exercise more seriously.
Even in cases where the use was discovered accidentally, the sentiment remains one of openness. Scott Disick, a father of three, became a subject of public discussion after Mounjaro was spotted in his refrigerator on The Kardashians. Disick, who gained weight following a 2022 car accident that limited his mobility, stated he was “not embarrassed” by his use of the medication.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications should only be used under the strict supervision of a licensed healthcare provider.
As the medical community continues to gather long-term data on the use of semaglutide and tirzepatide for weight loss, the focus is shifting toward sustainable maintenance and the prevention of muscle loss. The next major checkpoint for these therapies will be the results of ongoing long-term cardiovascular and metabolic outcome trials, which will determine if these drugs are a permanent fixture in the treatment of obesity or a temporary bridge to lifestyle change.
Do you believe the visibility of these treatments helps reduce the stigma for men’s health? Share your thoughts in the comments below.
